Free Trial

Eli Lilly and Company (LLY) Stock Forecast & Price Target

$949.37
+15.23 (+1.63%)
(As of 07/12/2024 ET)

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$843.00
-11.20% Downside
High Forecast$1,025.00
Average Forecast$843.00
Low Forecast$535.00
TypeCurrent Forecast
7/13/23 to 7/12/24
1 Month Ago
6/13/23 to 6/12/24
3 Months Ago
4/14/23 to 4/13/24
1 Year Ago
7/13/22 to 7/13/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
12 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$843.00$787.53$728.05$437.90
Forecasted Upside-11.20% Downside12.36% Upside10.87% Upside14.73% Upside
Get Eli Lilly and Company Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-11.11% Downside951.48% Upside9.38% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/11/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$850.00 ➝ $1,000.00+7.60%
7/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$900.00 ➝ $1,000.00+6.66%
7/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$913.00 ➝ $1,025.00+9.04%
7/5/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$1,023.00 ➝ $1,023.00+13.54%
7/3/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$1,001.00 ➝ $1,001.00+10.40%
7/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00-3.28%
6/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$892.00 ➝ $1,000.00+12.28%
6/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$994.00 ➝ $1,015.00+12.98%
6/24/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$1,000.00 ➝ $1,000.00+11.03%
5/14/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$770.00 ➝ $840.00+11.04%
4/11/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$650.00 ➝ $723.00-5.02%
4/3/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
4/2/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$675.00 ➝ $895.00+17.15%
2/21/2024DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$820.00+8.50%
2/6/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$700.00 ➝ $825.00+17.02%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$535.00-13.64%
10/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$612.00 ➝ $710.00+20.28%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
8/8/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$560.00+28.82%
6/27/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/1/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$410.00 ➝ $458.00+15.70%
4/28/20233M
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
4/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$395.00 ➝ $392.00+6.81%
2/15/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Sell$278.00-18.41%
12/16/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$384.00 ➝ $410.00+13.93%
12/5/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$390.00 ➝ $430.00+14.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:01 AM ET.

LLY Forecast - Frequently Asked Questions

What is Eli Lilly and Company's forecast for 2024?

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $843.00, with a high forecast of $1,025.00 and a low forecast of $535.00.

Should I buy or sell Eli Lilly and Company stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LLY shares.

Does Eli Lilly and Company's stock price have much upside?

According to analysts, Eli Lilly and Company's stock has a predicted upside of 9.33% based on their 12-month stock forecasts.

What analysts cover Eli Lilly and Company?

Eli Lilly and Company has been rated by research analysts at Argus, Bank of America, Barclays, Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, and Truist Financial in the past 90 days.

Do Wall Street analysts like Eli Lilly and Company more than its competitors?

Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.85 while the average consensus rating score for "medical" companies is 2.71. Learn more on how LLY compares to other companies.


This page (NYSE:LLY) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners